An Alternative Route — with Partners Collaborating on R&D, Licensing, Marketing: Less Risk and Less Margin

  • Stephanie Jones

Abstract

‘We’ve got four drugs on the market since 1985, being sold by a licensee. That, combined with reworking our commercial strategy, enabled us to begin building a very substantial revenue stream, from these drugs which are being sold by licensees in the form of royalties, which are going to permit us now to probably build revenues for the company over the next several years to well beyond the $100m level. Our principal licensees, Abbott Laboratories and Ortho Diagnostics, are gaining an increasingly large piece of the $250m world diagnostic market.

Keywords

Burner Hepatitis Carbide Europe Income 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© International Business Writing Limited 1992

Authors and Affiliations

  • Stephanie Jones

There are no affiliations available

Personalised recommendations